A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.
- Status
- recruiting
- Phase
- Phase 1
- Institution
- Francisco A Moreno
- Principal investigator
- Francisco Moreno, MD
- Start date
- 2026-05-18
- End date
- 2029-01-31
- Registry ID
- NCT07347405
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.